

GCET2 Antibody

Rabbit mAb Catalog # AP92085

Product Information

Application IHC, IF, FC, ICC, IHF

Primary Accession
Reactivity
Human
Clonality
Monoclonal

Other Names GCAT2; Gcet; Gcsam; hGAL; M17; M17 L;

IsotypeRabbit IgGHostRabbitCalculated MW21005

Additional Information

Dilution IHC 1:100~1:500 ICC/IF 1:100~1:500 FC 1:100

Purification Affinity-chromatography

Immunogen A synthesized peptide derived from human GCET2

Description Involved in the negative regulation of lymphocyte motility. It mediates the

migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK

kinase activation.

Storage Condition and Buffer Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium

azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term.

Avoid freeze / thaw cycle.

Protein Information

Name GCSAM

Synonyms GAL, GCET2

Function Involved in the negative regulation of lymphocyte motility. It mediates the

migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK

kinase activation.

Cellular Location Cytoplasm. Cell membrane. Note=It relocalizes from the cytoplasm to

podosome-like structures upon cell treatment with IL6

Tissue Location Expressed in diffuse large B-cell lymphoma (DLBCL) and several germinal

center (GC)-like lymphoma cell lines (at protein level). Highly expressed in normal GC lymphocytes and GC-derived malignancies. Expressed in thymus and spleen

Images

human bladder cancer, using GCET2 Antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.